Cost-effectiveness of trastuzumab deruxtecan as a second-line treatment for HER2-mutant advanced non-small cell lung cancer
The study of DESTINY-Lung01 and DESTINY-Lung02 demonstrated the favorable efficacy charcotabs and optimal dosage of trastuzumab deruxtecan (T-DXd) in managing the human epidermal growth factor receptor 2 (HER2)-mutant non-small cell lung cancer (NSCLC) patients who had received previous treatment.The study sought to assess the cost-effectiveness of